Evidence map›Paper›PMID 26855533›Full record

ReviewWorld journal of gastroenterology2016

Clinical and molecular features of young-onset colorectal cancer.

Veroushka Ballester, Shahrooz Rashtak, Lisa Boardman

Open access · hybridAbstract readReview
In one paragraph

Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed, 2 pooled it
13.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 2 syntheses or guidelines pooled it, 181 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Serum ferritin and the risk of early-onset colorectal cancer.World journal of gastrointestinal oncology · 2024
    Article
  17. Article
  18. Being Breastfed in Infancy and Risk of Colorectal Cancer and Precursor Lesions.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2024
    Article
  19. Article
  20. Focusing on colorectal cancer in young adults (Review).Molecular and clinical oncology · 2024
    Review

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Veroushka BallesterVeroushka Ballester, Shahrooz Rashtak, Lisa Boardman, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, United States.
Shahrooz RashtakVeroushka Ballester, Shahrooz Rashtak, Lisa Boardman, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, United States.
Lisa BoardmanVeroushka Ballester, Shahrooz Rashtak, Lisa Boardman, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, United States.
Mayo Clinic in Arizona · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is one of the leading causes of cancer related mortality worldwide. Although young-onset CRC raises the possibility of a hereditary component, hereditary CRC syndromes only explain a minority of young-onset CRC cases. There is evidence to suggest that young-onset CRC have a different molecular profile than late-onset CRC. While the pathogenesis of young-onset CRC is well characterized in individuals with an inherited CRC syndrome, knowledge regarding the molecular features of sporadic young-onset CRC is limited. Understanding the molecular mechanisms of young-onset CRC can help us tailor specific screening and management strategies. While the incidence of late-onset CRC has been decreasing, mainly attributed to an increase in CRC screening, the incidence of young-onset CRC is increasing. Differences in the molecular biology of these tumors and low suspicion of CRC in young symptomatic individuals, may be possible explanations. Currently there is no evidence that supports that screening of average risk individuals less than 50 years of age will translate into early detection or increased survival. However, increasing understanding of the underlying molecular mechanisms of young-onset CRC could help us tailor specific screening and management strategies. The purpose of this review is to evaluate the current knowledge about young-onset CRC, its clinicopathologic features, and the newly recognized molecular alterations involved in tumor progression.

Indexed as

Adenomatous Polyposis ColiAdultAge of OnsetAnimalsBiomarkers, TumorChromosomal InstabilityColorectal NeoplasmsColorectal Neoplasms, Hereditary NonpolyposisCpG IslandsDNA MethylationGenetic Predisposition to DiseaseHamartoma Syndrome, MultipleHeredityHumansIntestinal PolyposisMicrosatellite InstabilityBiomarkers, TumorChromosomal instabilityChromosome stable colorectal cancerCpG island methylator phenotypeLate-onset colorectal cancerMicrosatelliteMicrosatellite instabilityYoung-onset colorectal cancer

Identifiers

PMID26855533
PMCPMC4724605
OpenAlexW2415438454

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.